FDA says Unived sold four dietary supplements with website claims that make them unapproved new drugs.
What happened
FDA reviewed Unived's website in February and March 2021 and its Amazon product pages. FDA found claims that the products cure, mitigate, treat, or prevent disease. FDA says the products are therefore unapproved new drugs, and CalDveg, B12+D3, and D3+K2-7 also lack adequate directions for use.
What FDA found
Website and Amazon claims show the products are intended to treat or prevent disease, which makes them drugs.
FD&C Act section 201(g)(1)(B) [21 U.S.C. 321(g)(1)(B)]The products are new drugs because they are not generally recognized as safe and effective for the claimed uses and lack FDA approval.
FD&C Act sections 201(p), 301(d), and 505(a) [21 U.S.C. 321(p), 331(d), 355(a)]CalDveg, B12+D3, and D3+K2-7 lack adequate directions for use because they are intended for diseases not amenable to self-diagnosis or treatment without a licensed practitioner.
FD&C Act section 502(f)(1) [21 U.S.C. 352(f)(1)]; 21 CFR 201.5Introducing these misbranded drugs into interstate commerce violates the Act.
FD&C Act section 301(a) [21 U.S.C. 331(a)]
What FDA wants
FDA asks Unived to notify it in writing within 15 working days of receipt about the specific steps taken to fix the violations, how it will prevent recurrence, and related documentation. If it cannot complete the actions in that time, it must explain why and give a timeframe.
Who should pay attention
- dietary supplement brands that make disease claims
- online retailers and marketplaces listing supplements
- regulatory teams reviewing website and Amazon claims
This is a summary. Read the original letter on fda.gov.